多药耐药蛋白和 bcl-2 蛋白表达与初治急性白血病预后的关系

目的 探讨多药耐药蛋白和 bcl-2 蛋白表达与初治急性白血病 (AL)患者化疗效果的关系.方法 用流式细胞仪检测 29 例初诊未治AL患者多药耐药蛋白和 bcl-2 蛋白表达.结果 初治AL患者多药耐药蛋白和bcl-2蛋白表达率分别为 37.9% 和 83%;bcl-2 蛋白阳性与阴性患者的首次完全缓解(CR)情况经统计学分析显示差异无显著性(P＞0.05);而多药耐药蛋白阳性与阴性患者的首次完全缓解(CR)情况经统计学分析显示有显著性差异(P＜0.05);多药耐药蛋白和 bcl-2 蛋白两者之间无相关性.结论 多药耐药蛋白可作为预测初治AL患者化疗效果的敏感性指标.

The relationship between expression of multidrug resistance protein or bcl-2 protein and prognosis in newly diagnosed acute leukemia

Objective: To Evaluate the relationship between the expression of multidrug resistance protein or bcl-2 protein and prognosis in newly diagnosed AL patients. Methods: Immunochemistry and FCM methods were used to examine the expression of multidrug resistance protein and bcl-2 protein in 29 newly diagnosed acute leukemia (AL) patients. Results: The positive rate of multidrug resistance protein and bcl-2 protein expression in newly diagnosed AL was 37.9% and 83% respectively. The difference of the first complete remission rate in bcl-2 negative and in bcl-2 positive patients was not significant (P>0.05),but the difference of the first complete remission rate in multidrug resistance protein negative and in multidrug resistance protein positive patients was significant (P<0.05).There was no relationship between bcl-2 and multidrug resistance protein. Conclusion: Multidrug resistance protein is a good indicator to forecast prognosis in newly diagnosis leukemia patients.